Cargando…

Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4

BACKGROUND: Evaluate and compare the utility of serum folate receptor alpha (FRA) and megakaryocyte potentiating factor (MPF) determinations relative to serum CA125, mesothelin (MSLN) and HE4 for the diagnosis of epithelial ovarian cancer (EOC). METHODS: Electrochemiluminescent assays were developed...

Descripción completa

Detalles Bibliográficos
Autores principales:	O’Shannessy, Daniel J, Somers, Elizabeth B, Palmer, Leslie M, Thiel, Robert P, Oberoi, Pankaj, Heath, Ryan, Marcucci, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3640997/ https://www.ncbi.nlm.nih.gov/pubmed/23590973 http://dx.doi.org/10.1186/1757-2215-6-29

Ejemplares similares

Folate Receptor Alpha, Mesothelin and Megakaryocyte Potentiating Factor as Potential Serum Markers of Chronic Kidney Disease
por: Somers, Elizabeth B, et al.
Publicado: (2014)

Folate Receptor Alpha Expression in Lung Cancer: Diagnostic and Prognostic Significance
por: O'Shannessy, Daniel J., et al.
Publicado: (2012)

Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream(®) for Detecting (or Monitoring) the Expression of Folate Receptor Alpha
por: O’Shannessy, Daniel J., et al.
Publicado: (2016)

Expression of folate receptors alpha and beta in normal and cancerous gynecologic tissues: correlation of expression of the beta isoform with macrophage markers
por: O’Shannessy, Daniel J, et al.
Publicado: (2015)

Folate receptor alpha (FRA) expression in breast cancer: identification of a new molecular subtype and association with triple negative disease
por: O’Shannessy, Daniel J, et al.
Publicado: (2012)

Characterization of the Human Folate Receptor Alpha Via Novel Antibody-Based Probes
por: O'Shannessy, Daniel J., et al.
Publicado: (2011)

Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis
por: Kakimoto, Soichiro, et al.
Publicado: (2021)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
por: Chen, Shih-Hsun, et al.
Publicado: (2013)

Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in Pleural Effusions and Serum
por: Creaney, Jenette, et al.
Publicado: (2013)

Megakaryocytic Potentiating Factor and Mature Mesothelin Stimulate the Growth of a Lung Cancer Cell Line in the Peritoneal Cavity of Mice
por: Zhang, Jingli, et al.
Publicado: (2014)

Urine CA125 and HE4 for the Detection of Ovarian Cancer in Symptomatic Women
por: Barr, Chloe E., et al.
Publicado: (2023)

Novel antibody probes for the characterization of endosialin/TEM-1
por: O'shannessy, Daniel J., et al.
Publicado: (2016)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Co-expression of mesothelin and CA125/MUC16 is a prognostic factor for breast cancer, especially in luminal-type breast cancer patients
por: Einama, Takahiro, et al.
Publicado: (2021)

Influence of tumor microenvironment on prognosis in colorectal cancer: Tissue architecture-dependent signature of endosialin (TEM-1) and associated proteins
por: O'Shannessy, Daniel J., et al.
Publicado: (2014)

Meigs’ syndrome with elevated CA-125 and HE-4: a case of luteinized fibrothecoma
por: Danilos, Jaroslaw, et al.
Publicado: (2015)

The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer
por: WEI, SU, et al.
Publicado: (2016)

Urine CA125 and HE4 for the Triage of Symptomatic Women with Suspected Endometrial Cancer
por: Njoku, Kelechi, et al.
Publicado: (2022)

Assessment of levels of the tumor markers HE4 and CA125 considering staging, grading and histological types of endometrial cancer
por: Abdalla, Nabil, et al.
Publicado: (2016)

Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses
por: Terlikowska, Katarzyna M., et al.
Publicado: (2016)

The diagnosis and pathological value of combined detection of HE4 and CA125 for patients with ovarian cancer
por: Zheng, Li-e, et al.
Publicado: (2016)

Can the Determination of HE4 and CA125 Markers Affect the Treatment of Patients with Endometrial Cancer?
por: Cymbaluk-Płoska, Aneta, et al.
Publicado: (2021)

Diagnostic Value of Preoperative CA125, LDH and HE4 for Leiomyosarcoma of the Female Reproductive System
por: Zhang, Fenfen, et al.
Publicado: (2021)

Comparison of HE4, CA125, ROMA and CPH-I for Preoperative Assessment of Adnexal Tumors
por: Carreras-Dieguez, Núria, et al.
Publicado: (2022)

Are ROMA and HE4 More Accurate than CA-125, in Predicting of Ovarian Epithelial Carcinoma?
por: Behnamfar, Fariba, et al.
Publicado: (2023)

Feasibility of an Intensive, Disorder-Specific, Group-Based Cognitive Behavioural Therapy Intervention for Adolescents with Social Anxiety Disorder
por: O’Shannessy, Dustin M., et al.
Publicado: (2021)

Mesothelin-Specific Immune Responses and Targeted Immunotherapy for Mesothelin-Expressing Tumors
por: Einama, Takahiro, et al.
Publicado: (2017)

Gene Expression Analyses Support Fallopian Tube Epithelium as the Cell of Origin of Epithelial Ovarian Cancer
por: O’Shannessy, Daniel J., et al.
Publicado: (2013)

Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy
por: Nicolaides, Nicholas C., et al.
Publicado: (2014)

The Parsortix™ Cell Separation System—A versatile liquid biopsy platform
por: Miller, M. Craig, et al.
Publicado: (2018)

Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
por: Hamed, Elham O, et al.
Publicado: (2013)

Symptoms, CA125 and HE4 for the preoperative prediction of ovarian malignancy in Brazilian women with ovarian masses
por: Pitta, Denise da Rocha, et al.
Publicado: (2013)

Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review
por: Dochez, Vincent, et al.
Publicado: (2019)

Serum HE4 and CA125 combined to predict and monitor recurrence of type II endometrial carcinoma
por: Quan, Quan, et al.
Publicado: (2021)

Serum CA125 and HE4 as Biomarkers for the Detection of Endometrial Cancer and Associated High-Risk Features
por: Barr, Chloe E., et al.
Publicado: (2022)

Predicting value of HE4 and CA125 markers for optimal cytoreductive surgery in ovarian cancer patients
por: Saffarieh, Elham, et al.
Publicado: (2022)

The use of HE4, CA125 and CA72-4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer
por: Anastasi, Emanuela, et al.
Publicado: (2013)

Free CA125 promotes ovarian cancer cell migration and tumor metastasis by binding Mesothelin to reduce DKK1 expression and activate the SGK3/FOXO3 pathway
por: Huo, Qianyu, et al.
Publicado: (2021)

NAV-001, a high-efficacy antibody-drug conjugate targeting mesothelin with improved delivery of a potent payload by counteracting MUC16/CA125 inhibitory effects
por: Nicolaides, Nicholas C., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_r93bo2t1s3ciaav226fbpq70gc